Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Chiovato, L.
space
  arrow  Pinchera, A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens

right arrow Luca Chiovato, MD; Francesco Latrofa, MD; Lewis E. Braverman, MD; Furio Pacini, MD; Marco Capezzone, MD; Lucio Masserini, PhD; Lucia Grasso, PhD; and Aldo Pinchera, MD

2 September 2003 | Volume 139 Issue 5 Part 1 | Pages 346-351

Background: The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases.

Objective: To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity.

Design: Retrospective chart review study of patients treated and monitored with a standard prospective protocol.

Setting: University hospital in Pisa, Italy, between 1976 and 1994.

Patients: 182 patients with differentiated thyroid carcinoma and serum antibodies to thyroid peroxidase, thyroglobulin, or TSH receptor due to coexistent clinical Hashimoto thyroiditis, Graves disease, or focal autoimmune thyroiditis.

Intervention: Total thyroidectomy and radioiodine treatment to ablate residual or metastatic thyroid tissue. Regular follow-up with iodine-131 whole-body scanning and serum thyroglobulin measurement. Mean follow-up (±SD) was 10.1 ± 4.1 years (range, 4 to 20 years).

Measurements: Serum antibodies to thyroid peroxidase, thyroglobulin, and TSH receptor.

Results: Thyroid peroxidase, thyroglobulin, and TSH-receptor antibodies progressively disappeared after the initial treatment. The median disappearance time was 6.3 years for thyroid peroxidase antibodies and 3.0 years for thyroglobulin antibodies. There was a statistically significant correlation between the disappearance of thyroid tissue and that of thyroid antibodies. The coexistence of Hashimoto thyroiditis or Graves disease with thyroid cancer did not modify the pattern of disappearance of thyroid antibody compared with patients with focal autoimmune thyroiditis.

Conclusions: Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens, thus supporting the concept that continued antibody production depends on the persistence of autoantigen in the body.


Editors' Notes
space

Context

  • Theoretically, removal of thyroid tissue takes away inciting antigens and halts antibody production in patients with autoimmune thyroid disease.

Contribution

  • This retrospective study from a university thyroid disease center describes 4- to 20-year follow-up of 182 patients with differentiated thyroid carcinoma and thyroid antibodies due to coexistent autoimmune thyroid disease. After thyroidectomy and radioiodine treatment, thyroid peroxidase, thyroglubulin, and thyroid-stimulating hormone–receptor antibodies gradually disappeared in most patients.

Implications

  • Gradual disappearance of antibodies suggests that extrathyroidal tissues contribute to antibody production but that continued antibody production depends on persistence of thyroid antigens.

–The Editors

 

Author and Article Information
space

From Università di Pisa, Pisa, Italy; and Boston University School of Medicine, Boston, Massachusetts.

Drs. Chiovato and Latrofa contributed equally to this paper.

Grant Support: By the University of Pisa (Fondi d'Ateneo) and from the Ministero d'struzione, d'niversità e della Ricerca (MIUR), Rome, Italy.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Aldo Pinchera, MD, Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Ospedale di Cisanello, Via Paradisa 2, 56124 Pisa, Italy; e-mail, a.pinchera{at}endoc.med.unipi.it.

Current Author Addresses: Dr. Chiovato: Cattedra di Endocrinologia, Università di Pavia, U.O. di Endocrinologia, Fondazione Salvatore Maugeri I.R.C.C.S., Istituto di Pavia, Via Ferrata 8, 27100 Pavia, Italy.

Dr. Latrofa: Autoimmune Disease Unit, Cedars-Sinai Research Institute and University of California, Los Angeles School of Medicine, 8700 Beverly Boulevard, D-3057, Los Angeles, CA 90048.

Dr. Braverman: Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, 88 East Newton Street, Boston University School of Medicine, Boston, MA 02118.

Drs. Pacini, Capezzone, Pinchera, and Grasso: Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Ospedale di Cisanello, Via Paradisa 2, 56124 Pisa, Italy.

Dr. Masserini: Dipartimento di Statistica e Matematica Applicata all'Economia, Università di Pisa, Via Ridolfi 10, 56100 Pisa, Italy.

Author Contributions: Conception and design: L. Chiovato, F. Latrofa, A. Pinchera.

Analysis and interpretation of data: L. Chiovato, F. Latrofa, A. Pinchera.

Drafting of the article: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.

Critical revision of the article for important intellectual content: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.

Final approval of the article: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.

Provision of study materials or patients: L. Chiovato, F. Latrofa, F. Pacini, M. Capezzone, L. Grasso, A. Pinchera.

Statistical expertise: F. Latrofa, M. Capezzone, L. Masserini.

Obtaining of funding: A. Pinchera.

Administrative, technical, or logistic support: M. Capezzone.

Collection and assembly of data: F. Latrofa, M. Capezzone.


Related articles in Annals:

Summaries for Patients
Effects of Removing Thyroid Antigens in Patients with Autoimmune Thyroid Disease
Annals 2003 139: I-75. [Full Text]  



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
F. Latrofa, D. Ricci, L. Grasso, P. Vitti, L. Masserini, F. Basolo, C. Ugolini, G. Mascia, A. Lucacchini, and A. Pinchera
Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 591 - 596.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Menconi, M. Marino, A. Pinchera, R. Rocchi, B. Mazzi, M. Nardi, L. Bartalena, and C. Marcocci
Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1653 - 1658.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Salvi, G. Vannucchi, I. Campi, N. Curro, D. Dazzi, S. Simonetta, P. Bonara, S. Rossi, C. Sina, C. Guastella, et al.
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
Eur. J. Endocrinol., January 1, 2007; 156(1): 33 - 40.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Salvi, G. Vannucchi, I. Campi, S. Rossi, P. Bonara, F. Sbrozzi, C. Guastella, S. Avignone, G. Pirola, R. Ratiglia, et al.
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Eur. J. Endocrinol., April 1, 2006; 154(4): 511 - 517.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al.
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report
Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti
Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R Gorges, M Maniecki, W Jentzen, S. n-Y. Sheu, K Mann, A Bockisch, and O E Janssen
Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy
Eur. J. Endocrinol., July 1, 2005; 153(1): 49 - 55.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
E. L. Mazzaferri
Empirically Treating High Serum Thyroglobulin Levels
J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Latrofa, M. Phillips, B. Rapoport, and S. M. McLachlan
Human Monoclonal Thyroglobulin Autoantibodies: Epitopes and Immunoglobulin Genes
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5116 - 5123.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Spencer
Challenges of Serum Thyroglobulin (Tg) Measurement in the Presence of Tg Autoantibodies
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3702 - 3704.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2003 by the American College of Physicians.